---
title: "Pharmacotherapy in seniors with cardiovascular disease. | Sutter Health"
description: "Optimizing pharmacotherapy in seniors require research to determine optimal CVD therapy, reduce polypharmacy, increase adherence, and meet pt-centered goals."
url: "https://www.sutterhealth.org/research/publications/pharmacotherapy-in-seniors-with-cardiovascular-disease-1055312371"
---

1.  [Home](https://www.sutterhealth.org/) /
2.  [Research](https://www.sutterhealth.org/research) /
3.  [Research publications](https://www.sutterhealth.org/research/publications) /
4.  Pharmacotherapy in seniors with cardiovascular disease.

# Pharmacotherapy in older adults with cardiovascular disease: report from an American College of Cardiology, American Geriatrics Society, and National Institute on Aging workshop.

Schwartz JB, Schmader KE, Hanlon JT, Abernethy DR, Gray S, Dunbar-Jacob J, Holmes HM, Murray MD, Roberts R, Joyner M, Peterson J, Lindeman D, Tai-Seale M, Downey L, & Rich MW.

_J Am Geriatr Soc. 2018 Dec 7. doi: 10.1111/jgs.15634. \[Epub ahead of print\]_

2018-12-07

## Abstract

OBJECTIVES: To identify the top priority areas for research to optimize pharmacotherapy in older adults with cardiovascular disease (CVD).

DESIGN: Consensus meeting.SETTING: Multidisciplinary workshop supported by the National Institute on Aging, the American College of Cardiology, and the American Geriatrics Society, February 6-7, 2017.

PARTICIPANTS: Leaders in the Cardiology and Geriatrics communities, (officers in professional societies, journal editors, clinical trialists, Division chiefs), representatives from the NIA; National Heart, Lung, and Blood Institute; Food and Drug Administration; Centers for Medicare and Medicaid Services, Alliance for Academic Internal Medicine, Patient-Centered Outcomes Research Institute, Agency for Healthcare Research and Quality, pharmaceutical industry, and trainees and early career faculty with interests in geriatric cardiology.

MEASUREMENTS: Summary of workshop proceedings and recommendations.RESULTS: To better align older adults' healthcare preferences with their care, research is needed to improve skills in patient engagement and communication. Similarly, to coordinate and meet the needs of older adults with multiple comorbidities encountering multiple healthcare providers and systems, systems and disciplines must be integrated. The lack of data from efficacy trials of CVD medications relevant to the majority of older adults creates uncertainty in determining the risks and benefits of many CVD therapies; thus, developing evidence-based guidelines for older adults with CVD is a top research priority. Polypharmacy and medication nonadherence lead to poor outcomes in older people, making research on appropriate prescribing and deprescribing to reduce polypharmacy and methods to improve adherence to beneficial therapies a priority.

CONCLUSION: The needs and circumstances of older adults with CVD differ from those that the current medical system has been designed to meet. Optimizing pharmacotherapy in older adults will require new data from traditional and pragmatic research to determine optimal CVD therapy, reduce polypharmacy, increase adherence, and meet person-centered goals. Better integration of the multiple systems and disciplines involved in the care of older adults will be essential to implement and disseminate best practices.

[PubMed abstract](https://www.ncbi.nlm.nih.gov/pubmed/30536694)

## Research topics

-   [Aging and Longevity](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Aging+and+Longevity%5C%22%22)
-   [Cardiovascular Diseases](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Cardiovascular+Diseases%5C%22%22)
-   [Pharmacoepidemiology](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Pharmacoepidemiology%5C%22%22)

## Related publications

[View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication)

-   Publication
    
    ### [Adherence to placebo and mortality in the Beta Blocker Evaluation of Survival Trial (BEST).](https://www.sutterhealth.org/research/publications/placebo-and-mortality-in-beta-blocker-eval-of-survival-trial-1055312716)
    
    Pressman A, Avins AL, Neuhaus J, Ackerson L, Rudd P.
    
    Contemp Clin Trials. 33(3):492-8. doi: 10.1016/j.cct.2011.12.003. Epub 2012 Jan 12.
    
    2012 May 01
    
-   Publication
    
    ### [Statin dosing instructions, medication adherence, and low-density lipoprotein cholesterol: a cohort study of incident statin users.](https://www.sutterhealth.org/research/publications/cohort-study-of-incident-statin-users-1055312767)
    
    Marcum ZA, Huang HC, Romanelli RJ.
    
    J Gen Intern Med. doi: 10.1007/s11606-019-05180-7. \[Epub ahead of print\]
    
    2019 Jul 31
    
-   Publication
    
    ### [Dabigatran versus warfarin for atrial fibrillation in real-world clinical practice: a systematic review and meta-analysis.](https://www.sutterhealth.org/research/publications/dabigatran-vs-warfarin-atrial-fibrillation-1055312522)
    
    Romanelli RJ, Nolting L, Dolginsky M, Kym E, Orrico KB.
    
    Circ Cardiovasc Qual Outcomes. pii: CIRCOUTCOMES.115.002369. \[Epub ahead of print\]
    
    2016 Jan 26
    
-   Publication
    
    ### [Clopidogrel pharmacogenomics: next steps: a clinical algorithm, gene-gene interactions, and an elusive outcomes trial.](https://www.sutterhealth.org/research/publications/clopidogrel-pharmacogenomics-1055312893)
    
    Gladding P1, Panattoni L, Webster M, Cho L, Ellis S.
    
    JACC Cardiovasc Interv. 3(10):995-1000. doi: 10.1016/j.jcin.2010.08.012.
    
    2010 Oct 01
    
-   Publication
    
    ### [Thoracic aorta calcification and noncardiovascular disease-related mortality: the multi-ethnic study of atherosclerosis.](https://www.sutterhealth.org/research/publications/thoracic-aorta-calcification-and-non-cvd-mortality-1055312467)
    
    Thomas IC, Thompson CA, Yang M, Allison MA, Forbang NI, Michos ED, McClelland RL, Budoff MJ, Criqui MH.
    
    Arterioscler Thromb Vasc Biol. pii: ATVBAHA.118.310850. doi: 10.1161/ATVBAHA.118.310850. \[Epub ahead of print\]
    
    2018 Jun 28
    

[View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication)

```json
{"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]}
```

```json
{"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/publications/pharmacotherapy-in-seniors-with-cardiovascular-disease-1055312371#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Research publications","item":"https://www.sutterhealth.org/research/publications"},{"@type":"ListItem","position":4,"name":"Pharmacotherapy in seniors with cardiovascular disease."}]}
```

```json
{"@context":"https://schema.org","@type":"MedicalScholarlyArticle","@id":"https://www.sutterhealth.org/research/publications/pharmacotherapy-in-seniors-with-cardiovascular-disease-1055312371#medicalscholarlyarticle","name":"Pharmacotherapy in older adults with cardiovascular disease: report from an American College of Cardiology, American Geriatrics Society, and National Institute on Aging workshop.","headline":"Pharmacotherapy in seniors with cardiovascular disease.","abstract":"OBJECTIVES: To identify the top priority areas for research to optimize pharmacotherapy in older adults with cardiovascular disease (CVD). DESIGN: Consensus meeting.SETTING: Multidisciplinary workshop supported by the National Institute on Aging, the American College of Cardiology, and the American Geriatrics Society, February 6-7, 2017. PARTICIPANTS: Leaders in the Cardiology and Geriatrics communities, (officers in professional societies, journal editors, clinical trialists, Division chiefs), representatives from the NIA; National Heart, Lung, and Blood Institute; Food and Drug Administration; Centers for Medicare and Medicaid Services, Alliance for Academic Internal Medicine, Patient-Centered Outcomes Research Institute, Agency for Healthcare Research and Quality, pharmaceutical industry, and trainees and early career faculty with interests in geriatric cardiology. MEASUREMENTS: Summary of workshop proceedings and recommendations.RESULTS: To better align older adults' healthcare preferences with their care, research is needed to improve skills in patient engagement and communication. Similarly, to coordinate and meet the needs of older adults with multiple comorbidities encountering multiple healthcare providers and systems, systems and disciplines must be integrated. The lack of data from efficacy trials of CVD medications relevant to the majority of older adults creates uncertainty in determining the risks and benefits of many CVD therapies; thus, developing evidence-based guidelines for older adults with CVD is a top research priority. Polypharmacy and medication nonadherence lead to poor outcomes in older people, making research on appropriate prescribing and deprescribing to reduce polypharmacy and methods to improve adherence to beneficial therapies a priority. CONCLUSION: The needs and circumstances of older adults with CVD differ from those that the current medical system has been designed to meet. Optimizing pharmacotherapy in older adults will require new data from traditional and pragmatic research to determine optimal CVD therapy, reduce polypharmacy, increase adherence, and meet person-centered goals. Better integration of the multiple systems and disciplines involved in the care of older adults will be essential to implement and disseminate best practices.","description":"Optimizing pharmacotherapy in seniors require research to determine optimal CVD therapy, reduce polypharmacy, increase adherence, and meet pt-centered goals.","keywords":["Aging and Longevity","Cardiovascular Diseases","Pharmacoepidemiology"],"datePublished":"2018-12-07","url":"https://www.sutterhealth.org/research/publications/pharmacotherapy-in-seniors-with-cardiovascular-disease-1055312371","inLanguage":"en-US","identifier":[{"@type":"PropertyValue","propertyID":"PMID","value":"30536694"},{"@type":"PropertyValue","propertyID":"DOI","value":"10.1111/jgs.15634"}],"sameAs":["https://pubmed.ncbi.nlm.nih.gov/30536694/","https://doi.org/10.1111/jgs.15634"],"isPartOf":{"@type":"Periodical","name":"J Am Geriatr Soc"},"author":[{"@type":"Person","name":"Schwartz JB"},{"@type":"Person","name":"Schmader KE"},{"@type":"Person","name":"Hanlon JT"},{"@type":"Person","name":"Abernethy DR"},{"@type":"Person","name":"Gray S"},{"@type":"Person","name":"Dunbar-Jacob J"},{"@type":"Person","name":"Holmes HM"},{"@type":"Person","name":"Murray MD"},{"@type":"Person","name":"Roberts R"},{"@type":"Person","name":"Joyner M"},{"@type":"Person","name":"Peterson J"},{"@type":"Person","name":"Lindeman D"},{"@type":"Person","name":"Tai-Seale M"},{"@type":"Person","name":"Downey L"},{"@type":"Person","name":"Rich MW"}],"sourceOrganization":{"@type":"MedicalOrganization","name":"Palo Alto Medical Foundation Research Institute"},"about":[{"@type":"DefinedTerm","name":"Aging and Longevity","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Aging+and+Longevity%22%5D%7D%5D&verticalKey=research_publication"},{"@type":"DefinedTerm","name":"Cardiovascular Diseases","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Cardiovascular+Diseases%22%5D%7D%5D&verticalKey=research_publication"},{"@type":"DefinedTerm","name":"Pharmacoepidemiology","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Pharmacoepidemiology%22%5D%7D%5D&verticalKey=research_publication"}],"mainEntityOfPage":{"@type":"WebPage","@id":"https://www.sutterhealth.org/research/publications/pharmacotherapy-in-seniors-with-cardiovascular-disease-1055312371","breadcrumb":{"@id":"https://www.sutterhealth.org/research/publications/pharmacotherapy-in-seniors-with-cardiovascular-disease-1055312371#breadcrumblist"}}}
```
